Know-how firm Tempus has introduced the launch of the brand new minimal residual illness (MRD) assay, xM, designed for colorectal most cancers (CRC) analysis.
The xM assay is a tumour-naïve, plasma-based take a look at that detects circulating tumour DNA (ctDNA) in blood samples from sufferers with early-stage CRC following surgical procedure.
At present obtainable for analysis use solely, the xM assay represents a liquid biopsy strategy to MRD evaluation that doesn’t require baseline tumor tissue. It gives a binary MRD consequence utilizing each methylation and genomic variant classifiers.
The assay incorporates algorithms to filter out artifacts, CHIP and germline variants.
The purpose of xM is to determine and monitor sufferers with low ranges of ctDNA who could also be prone to recurrence, probably guiding extra aggressive or post-surgical remedies.
Tempus chief scientific officer Kate Sasser mentioned: “Colorectal most cancers is the second main reason for cancer-related deaths worldwide, and surgical intervention alone might not be healing for all sufferers. Rising information means that sufferers could profit from diagnostic checks that may detect recurrence with extra analytical sensitivity in comparison with customary surveillance mechanisms like imaging.
Entry essentially the most complete Firm Profiles
available on the market, powered by GlobalData. Save hours of analysis. Acquire aggressive edge.
Firm Profile – free
Your obtain e-mail will arrive shortly
We’re assured in regards to the
high quality of our Firm Profiles. Nonetheless, we wish you to take advantage of
choice for your enterprise, so we provide a free pattern that you may obtain by
submitting the beneath kind
“We’re excited to introduce a blood-based MRD take a look at that may rapidly assess if a affected person is prone to recurrence with excessive specificity and sensitivity, and xM is a superb complement to our rising portfolio of diagnostics as it’s a very useful device for sufferers earlier of their therapy journey.”
Tempus can also be conducting extra scientific validation research to probably improve these efficiency metrics.
With the addition of xM to its product suite, Tempus now presents two distinct MRD assays.
The corporate’s portfolio additionally consists of the tumour-informed take a look at NeXT.
In November 2023, Tempus introduced the new ctDNA assay, xF Monitor, for use for analysis functions solely.